参考文献/References:
[1] BACHANOVA V,PERALES M A,ABRAMSON J S.Modern management of relapsed and refractory aggressive B-cell lymphoma:a perspective on the current treatment landscape and patient selection for CAR T-cell therapy [J].Blood reviews,2020,40:1-7.[2] ABRAMSON J S.Anti-CD19 Car T-cell therapy for B-cell Non-hodgkin lymphoma [J].Transfus Med Rev,2020,34(1):29-33.[3] NEELAPU S S.Managing the toxicities of CAR T-cell therapy [J].Hematolog Oncol,2019,37(s1):48-52.[4] 孟瑞,徐丽,万滢.CAR-T免疫疗法在血液系统恶性肿瘤病人中的应用进展[J].护理研究,2020,34(10):1759-1763.[5] BONIFANT B L,JACKON H J,BRENTJENS R J,et al.Toxicity and management in CAR T-cell therapy[J].Mol Ther Oncol,2016,3:16011.[6] PABST T,JONCOURT R,SHUMILOV E,et al.Analysis of IL-6 serum levels and CAR-T cell specific digital PCR in the context of cytokine release syndrome(CRS)[J].Experiment Hematol,2020,13(88):7-14.[7] 阮海涛,万滢,徐丽.嵌合抗原受体T细胞治疗恶性血液肿瘤并发重度细胞因子释放综合征患者的护理[J].护理学杂志,2019,34(23):29-31.[8] 李丽娜,万滢.嵌合抗原受体修饰T细胞免疫疗法治疗B细胞恶性肿瘤患者的护理[J].中华护理杂志,2017,52(3):297-299.[9] GAUTHIER J,TURTLE C J.Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy[J].Curr Res Transl Med,2018,66(2):50-52.[10]张佳佳,赵万红.CAR-T细胞免疫治疗相关的不良反应研究进展[J].现代肿瘤医学,2020,28(12):2159-2164.[11]刘兆楠,韩为东,蒋敬庭.CAR-T细胞治疗的神经毒性副反应处理新策略[J].中国肿瘤生物治疗杂志,2019,26(6):617-622.[12]CAROLYN S H,KATHRYN T N,JENNIFER P,et al.Implementation of a standardized assessment for neurotoxicity in patients receving chimeric antigen receptor(CAR)T-cell therapies on an inpatient hematology unit[J].Biol blood marrow transplant,2019,25:432.[13]张佳思,黎宁,阮潜瑛,等.嵌合抗原受体T细胞治疗血液肿瘤患者规范化护理体系的构建[J].解放军护理杂志,2018,35(22):1-6.(本文编辑:陈晓英)